NCT07153705View on ClinicalTrials.gov

OCS Products Based on Exosome Technology Were Applied in the Recurrence Monitoring Study After the Initial Treatment of Baseline CA125-negative Ovarian Cancer

Not yet recruitingOBSERVATIONAL

Enrollment

32

Participants

Timeline

Start Date

September 1, 2025

Primary Completion Date

April 1, 2026

Study Completion Date

April 1, 2026

Conditions

Ovarian Cancer

All Listed Sponsors

lead

Beihua Kong

OTHER